Cost of Illness Analysis of Human Immuno Deficiency Virus/ACQUIRED Immuno Deficiency Syndrome (HIV/AIDS) in a Developing Economy.
No Thumbnail Available
Date
2018
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
West African Postgraduate College of Pharmacy
Abstract
Background: Highly Active Antiretroviral Therapy is for lifetime of the patients from time of diagnosis
of HIV/AIDS. This translates into a substantial cost in drug therapy to the patients, government and
donor agencies.
Objective: To conduct cost of illness analysis of HIV/AIDS in a Developing Economy in 2016.
Methods: A one-year retrospective review of 2560 prescriptions of 396 HIV/AIDS patients' case notes
from January to December, 2016 obtained by systematic random sampling from 4800 case-notes of
subjects that participated in this study was conducted. Sampling Interval =10
A data collection form was designed and used to collect data generated from the selected case notes.
Cost of Illness was determined by prevalence rate method, using direct costs only.
Results: The annual cost of illness for the 396 HIV/AIDS patients on highly active antiretroviral
therapy was ?40,674,760 (US$127,108.3) with drug, diagnostic/monitoring tests, transport,
care/support and personnel cost components of ?25,479,760; US$79,624.3 (62.64%), ?7,200,000;
US$22,500 (17.71%), ?1,440,000; US$4,500(3.54%), ?2,880,000; US$9,000 (7.08%) and ?3,675,000;
US$11484 (9.03%) respectively. The annual average cost of illness of HIV/AIDS was ?102,714.04
(US$320.98)
Conclusion: The annual average cost of illness of HIV/AIDS represent 97% of annual per capita
income. This is enormous. The Annual National cost of illness for HIV/AIDS in Nigeria, a developing
economy may be about N590 billion annually
Description
Keywords
Cost of Illness, Analysis, HIV/AIDS, Developing economy
Citation
Giwa A, Giwa HBF, Jamiu MO (2018): Cost of Illness Analysis of Human Immuno Deficiency Virus/ACQUIRED Immuno Deficiency Syndrome (HIV/AIDS) in a Developing Economy. West African Journal of Pharmacy. 29(2); 44-52, Published by West African Postgraduate College of Pharmacy.